• 1
    Merlini G, Belotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 58396.
  • 2
    Van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54: 201521.
  • 3
    Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 1997; 337: 898909.
  • 4
    Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007; 48: 86572.
  • 5
    Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butriiene I, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14: 13340.
  • 6
    Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006; 119: 355. e15–24.
  • 7
    Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962; 10: 35563.
  • 8
    Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis; 2004 April 18–22; Tours, France. Am J Hematol 2005; 79: 31928.
  • 9
    Reyners AK, Hazenberg BP, Haagsma EB, Tio RA, Reitsma WD, Smit AJ. The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid 1998; 5: 1939.
  • 10
    Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998; 39: 699706.
  • 11
    Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 6912.
  • 12
    Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burnitt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 37517.
  • 13
    Palladini G, Campana C, Klersy C, Baldini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 24405.
  • 14
    Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Morner S, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263: 294301.
  • 15
    Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008; 15: 408.
  • 16
    Haagsma EB, van Gameren II, Bijzet J, Posthumus MD, Hazenberg BP. Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation. Amyloid 2007; 14: 2216.
  • 17
    Van Gameren II, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94: 1094100.